NCT03670069 2024-05-08
Itacitinib in Treating Patients With Refractory Metastatic/Advanced Sarcomas
Fred Hutchinson Cancer Center
Phase 1 Terminated
Clinical Trials
3 trialsNCT03272464 2023-09-22
INCB039110 in Combination With Dabrafenib and Trametinib in Patients With BRAF-mutant Melanoma and Other Solid Tumors.
Massachusetts General Hospital
Phase 1 Terminated
NCT03425006 2023-09-13
Pembrolizumab and Itacitinib (INCB039110) for Non-Small Cell Lung Cancer
University of Pennsylvania
Phase 2 Terminated